You are here

Novartis

What happened a year ago this week in biopharma? August 12-18, 2018

What happened a year ago this week in biopharma? August 12-18, 2018

CP WIre

Vertex Pharmaceuticals

cystic fibrosis

Bristol-Myers Squibb

Flag link:

What happened a year ago this week in biopharma? August 12-18, 2018

Vertex Pharmaceuticals

cystic fibrosis

Bristol-Myers Squibb

Flag link:

Warning signs were always there for Novartis’s Avexis deal

Warning signs were always there for Novartis’s Avexis deal

EP Vantage

Flag link:

AveXis scientific founder is out as Novartis names a new CSO in wake of an ethics scandal

AveXis scientific founder is out as Novartis names a new CSO in wake of an ethics scandal

Endpoints

Flag link:

Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi

Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi

Pharmaceutical Business Review

Flag link:

Novartis names Bulto as new head of U.S. drugs business

Novartis names Bulto as new head of U.S. drugs business

Yahoo/Reuters

Flag link:

Novartis inspection puts into question who knew what—and when—about Zolgensma data manipulation

Novartis inspection puts into question who knew what—and when—about Zolgensma data manipulation

Fierce Pharma

Flag link:

5 Biggest New Drugs Approved in 2019 So Far

5 Biggest New Drugs Approved in 2019 So Far

Motley Fool

multiple sclerosis

metastatic bladder cancer

Flag link:

Questions pile up for Novartis as senators call on FDA to take action

Questions pile up for Novartis as senators call on FDA to take action

Endpoints

Flag link:

Novartis sells phase 3 rare disease drug to Pharming

Novartis sells phase 3 rare disease drug to Pharming

Fierce Biotech

Flag link:

Questions Pile up for Novartis as Senators Call on FDA to Take Action

Questions Pile up for Novartis as Senators Call on FDA to Take Action

RAPS.org

Flag link:

5 Reasons Novartis Shareholders Aren't Shaken

5 Reasons Novartis Shareholders Aren't Shaken

Yahoo/Motley Fool

Flag link:

Novartis resolute that it acted in good faith on Zolgensma

Novartis resolute that it acted in good faith on Zolgensma

BioCentury

Flag link:

Novartis used manipulated data in winning Zolgensma approval, FDA says

Novartis used manipulated data in winning Zolgensma approval, FDA says

Biopharma Dive

spinal muscular atrophy

Flag link:

Novartis' Kisqali sharpens survival edge with second ph3 win

Novartis' Kisqali sharpens survival edge with second ph3 win

Fierce Pharma

clinical trials

Flag link:

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

Endpoints

Flag link:

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

Yahoo/Reuters

Flag link:

Novartis’ Zolgensma Joins Growing List of Medicines to Lose Accelerated Assessment Status in EU

Novartis’ Zolgensma Joins Growing List of Medicines to Lose Accelerated Assessment Status in EU

RAPS.org

Flag link:

Novartis heart drug fails trial, curbing growth prospects

Novartis heart drug fails trial, curbing growth prospects

Yahoo/Reuters

clinical trials

Flag link:

Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis

Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis

Pharmaceutical Business Review

clinical trials

Flag link:

Pages